Press releases
- Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis
- Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
- Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
- Quest Diagnostics Declares Quarterly Cash Dividend
- Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
- Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
- Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
More ▼
Key statistics
As of last trade Quest Diagnostics Inc (DGX:DEU) traded at 129.30, -3.22% below its 52-week high of 133.60, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 130.95 |
---|---|
High | 131.40 |
Low | 129.30 |
Bid | 127.95 |
Offer | 128.95 |
Previous close | 130.75 |
Average volume | 21.30 |
---|---|
Shares outstanding | 111.09m |
Free float | 110.61m |
P/E (TTM) | 18.94 |
Market cap | 15.64bn USD |
EPS (TTM) | 7.43 USD |
Annual div (ADY) | 2.78 EUR |
---|---|
Annual div yield (ADY) | 2.15% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Next div ex-date | Jul 08 2024 |
Next div pay-date | Jul 22 2024 |
Data delayed at least 15 minutes, as of Jun 12 2024.
More ▼